Patent for LegoChem antibody-drug conjugate platform

LegoChem Biosciences said it was awarded a US patent entitled “antibody-active agent conjugates and methods of use.”

LegoChem said the patent illustrates the company’s ConjuAll technology, a proprietary antibody-drug conjugate (ADC) platform “which enables the design of homogeneous plasma stable ADCs with the potential for improved payload delivery to cancer cells.”

Dr. Yeong Soo Oh, Chief Technology Officer of LCB said: “This patent further strengthens LCB’s competitive advantage in the field of research and development of next generation ADCs.

“The use of our technology will address significant unmet needs of current ADC technologies.”